Sa1251 Ultrasound-Mediated Gastrointestinal Drug Delivery for Ulcerative Colitis

Schoellhammer, Carl M.; Schroeder, Avi; Maa, Ruby; Brugge, William R.; Lauwers, Gregory Y.; Anderson, Daniel G.; Blankschtein, Daniel; Langer, Róbert; Traverso, Giovanni

doi:10.1016/s0016-5085(15)30891-x

Gastroenterology

2015

DOI: 10.1016/s0016-5085(15)30891-x

|View full text |Cite

Sa1251 Ultrasound-Mediated Gastrointestinal Drug Delivery for Ulcerative Colitis

Carl M. Schoellhammer¹,

Avi Schroeder²,

Ruby Maa³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent article by Schoellhammer et al, "Ultrasoundmediated gastrointestinal drug delivery" primarily addresses practical limitations in drug delivery for medical management of inflammatory bowel disease (IBD), and presents pre-clinical data demonstrating that intraluminal, sub-ablative focused ultrasound (FUS), delivered via a trans-rectal transducer, can overcome some of these limitations (1). The clinical application and benefit of such a device is clear.…”

mentioning

confidence: 99%

Intra-luminal focused ultrasound for augmentation of gastrointestinal drug delivery

Maloney

Hwang

2017

Annals of Translational Medicine

View full text Add to dashboard Cite

The recent article by Schoellhammer et al., "Ultrasoundmediated gastrointestinal drug delivery" primarily addresses practical limitations in drug delivery for medical management of inflammatory bowel disease (IBD), and presents pre-clinical data demonstrating that intraluminal, sub-ablative focused ultrasound (FUS), delivered via a trans-rectal transducer, can overcome some of these limitations (1). The clinical application and benefit of such a device is clear. Currently, outpatient treatment of proctitis/ proctosigmoiditis can involve patient self-administration of an anti-inflammatory drug enema (e.g., mesalamine, hydrocortisone) that is ideally retained overnight to maximize medication absorption (2,3). Compliance with this regimen can be highly challenging for patients with active colitis as symptoms include urgency and frequent bowel movements. Methods to improve the efficiency of drug transit/tissue penetration and thus decrease both the frequency of enema administration as well the required mucosal exposure time to the enema would likely be welcomed by patients. Improved compliance on this more rapid regimen could theoretically help to mitigate the long-term sequelae of under-treated disease. An important question raised and discussed in this article is how to expand upon this particularly well-suited clinical application to improve targeted drug delivery (TDD) to other areas of the gastrointestinal (GI) tract.Ex vivo experiments were performed on samples of tissue taken from throughout the porcine GI tract. These were mounted and exposed to variable, relatively low intensity ultrasound frequencies followed by quantification of delivery of permeants (e.g., glucose, dextran, insulin). Treated tissues showed enhanced transport. Similar findings were demonstrated in small and large bowel tissue for radiolabeled mesalamine and hydrocortisone. With 1 minute of ultrasound treatment time, 3-5-fold improved drug delivery was observed versus control. Additional ex vivo experiments utilizing variable FUS protocols to alter the thermal, radiative force, and cavitation effects of FUS therapy demonstrated drug delivery to be enhanced primarily through transient cavitation effects.In vivo, both pigs and mice were used to assess the safety and efficacy of treatment with trans-rectal FUS transducer models. These studies revealed no evidence of ultrasoundinduced injury, a ~22-fold increase in mesalamine uptake in treated tissue with concurrent mesalamine enema, and effective ultrasound-driven absorption and systemic response to concurrent insulin enema. A mouse model of dextran sodium sulfate induced colitis showed significantly faster recovery (assessed by total fecal score and histologic response) in mice treated with either daily or every-otherday FUS and mesalamine enema versus daily enema alone. These results support the idea that clinical application of FUS-augmented mesalamine enema in IBD can improve both drug transit/tissue penetration, as well as clinical outcomes for patients with poor tolerance of daily enema...

show abstract

mentioning

confidence: 99%

Intra-luminal focused ultrasound for augmentation of gastrointestinal drug delivery

Maloney

Hwang

2017

Annals of Translational Medicine

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sa1251 Ultrasound-Mediated Gastrointestinal Drug Delivery for Ulcerative Colitis

Cited by 1 publication

References 0 publications

Intra-luminal focused ultrasound for augmentation of gastrointestinal drug delivery

Intra-luminal focused ultrasound for augmentation of gastrointestinal drug delivery

Contact Info

Product

Resources

About